PACERR (PTGS2 Antisense NFKB1 Complex-Mediated Expression Regulator RNA)

This preliminary study demonstrates its potential anticancer, antibacterial, antioxidant, and anti-inflammatory activities in vitro. However, further detailed investigations, including more extensive in vitro studies as well as in vivo evaluations, are required to better elucidate its mechanisms, safety, and potential biological applications.

Notably, despite AME alone increasing oxidative stress markers (oxidized glutathione), coordinated antioxidant responses (nrf2, sod2, gpx1a) were only triggered in co-exposed group. Our findings demonstrate that TiO2 NPs potentiate AME-induced metabolic rewiring and neuroinflammation at physiologically relevant levels, underscoring the necessity to reassess combined toxicities of emerging contaminants through pathway-based approaches.

Docking analysis identified apigenin and kaempferol with the lowest binding energy against PTGS2 and EGFR, respectively, while flavonol glycoside showed the lowest binding energy against MMP9. However, detailed research is needed to isolate the potential phytochemicals from J. mimosifolia against HCC.

Crucially, the addition of exogenous PGE2 restored VM formation in celecoxib-treated cells, confirming that celecoxib-mediated VM suppression is dependent on the reduction of PGE2 levels. These findings establish the COX-2/PGE2 signaling axis as a key regulator of VM in D17 canine osteosarcoma cells and that celecoxib warrants further preclinical evaluation as a strategy to target both tumor growth and alternative vascularization.

Molecular docking showed strong interactions with APP, HSP90AA1, and AKT1, while MD simulations validated the long-term stability of ε-viniferin within the APP binding pocket. These findings provide mechanistic insights into viniferin as a multi-target agent for HCC, justifying further experimental validation in pre-clinical models.

Inosine inhibits the activation of the PI3K/AKT signaling pathway. Inosine exerted an inhibitory effect on colorectal cancer liver metastasis by skewing macrophages toward an M1 phenotype, dampening pro-inflammatory cytokine release, and regulating key genes via the PI3K/AKT pathway.

Complexes based on naproxen, ibuprofen, and salicylic acid derivatives display potent antiproliferative activity against Caco-2/TC7 colon cancer cells, outperforming oxaliplatin and being comparable to auranofin, while showing markedly reduced cytotoxicity in breast cancer lines and nonmalignant cells, thus indicating promising selectivity. Additionally, complex 1 selectively inhibits the enzyme cyclooxygenase-2 (COX-2) over COX-1 and reduces IL-8 expression without affecting PTGS2 transcription, highlighting a post-transcriptional anti-inflammatory action. These results support NSAID-derived alkynyl gold(I) complexes as promising multitarget agents for colorectal cancer intervention, combining disruption and COX-2 modulation.

Our findings elucidate multiple mechanisms by which CGs may exert anti-LSC activity, which could be crucial for the design of novel therapeutic strategies for AML. The proposed in silico framework is broadly applicable and may accelerate drug repurposing in AML and other cancers.

Collectively, these findings demonstrate that CAFs acquire a distinct inflammatory signature that differs from gingival fibroblasts and promotes tumor invasion and progression. Targeting CAF-associated inflammatory and signaling pathways may represent a promising strategy to overcome tumor infiltration and treatment resistance in oral cancer.

Liquidambaris Fructus can target PTGS2 and TGFB1 to inhibit osteosarcoma cell growth and metastasis, as well as to inhibit efferocytosis, thus alleviating osteosarcoma.

NTSR1 is a key oncogenic driver in LUAD. Liensinine is a novel NTSR1 antagonist that suppresses tumors by selectively inhibiting Gq signaling and reprogramming the transcriptional landscape.